Disease: Multiple myeloma
- A case report of biclonal immunoglobulin D lambda/lambda multiple myeloma in patient with liver echinococcosis
- A comparative analysis of transcriptomics of newly diagnosed multiple myeloma: exploring drug repurposing
- A Deeper Depth of Response After Salvage Therapy Improves Outcomes of Autologous Stem Cell Transplantation in Relapsed Lymphoma and the Feasibility of Non-controlled Rate Freezing of Peripheral Blood Stem Cells
- A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients
- An adaptive seamless 2-in-1 design with biomarker-driven subgroup enrichment
- Analysis of the efficacy of separation surgery for severe neurological compression in multiple myeloma: a retrospective analysis of 35 cases
- Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?
- Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review
- ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study
- Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study
- Association of residential exposure to hazardous air pollutants with risk of non-Hodgkin lymphoma and multiple myeloma
- Batimastat Induces Cytotoxic and Cytostatic Effects in In Vitro Models of Hematological Tumors
- Biological Age is No Barrier for Adult Patients Undergoing CAR T for Non-Hodgkin's Lymphoma or Multiple Myeloma
- Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives
- Bortezomib elevates intracellular free Fe(2+) by enhancing NCOA4-mediated ferritinophagy and synergizes with RSL-3 to inhibit multiple myeloma cells
- Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma
- Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations
- Circ_0005615 enhances multiple myeloma progression through interaction with EIF4A3 to regulate MAP3K4 m6A modification mediated by ALKBH5
- Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis
- Clinical Efficacy and Safety of Ixazomib-Containing Regimens in the Treatment of Patients with Multiple Myeloma
- Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single Institution
- Clinicopathologic conference: Bloodstream infection in an allogeneic hamatopoietic cell transplant: Thinking beyond the usual
- Co-operation of MCL-1 and BCL-X<sub>L</sub> anti-apoptotic proteins in stromal protection of MM cells from carfilzomib mediated cytotoxicity
- Complex Pathological Femoral Fracture in a Multiple Myeloma Patient Undergoing Intertrochanteric Fixation: A Case Report
- Comprehensive evaluation of genetic and acquired thrombophilia markers for an individualized prediction of clinical thrombosis in patients with lymphoma and multiple myeloma
- Construction of immune-related gene pairs signature to predict the overall survival of multiple myeloma patients based on whole bone marrow gene expression profiling
- Correlation between CRAB Symptoms and Antioxidant Enzyme Activity in Patients with Multiple Myeloma
- Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1
- Cyclophosphamide, Bortezomib, and Dexamethasone and Severe Systolic Heart Failure: A Case Report
- Cytomegalovirus Reactivation During Elotuzumab Therapy in Patients with Multiple Myeloma
- Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant
- Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
- Daratumumab-resistant multiple myeloma with extramedullary disease successfully treated with combination elotuzumab, pomalidomide and dexamethasone: A case report
- Decreased RNA-binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide
- Diagnostic value of LGE and T1 mapping in multiple myeloma patients'heart
- Editorial: Linking cellular metabolism to hematological malignancies, volume II
- Effect of Recombinant Human Thrombopoietin on Platelet Reconstitution after Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma
- Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden
- Effects of Different Nutritional Scoring Systems on Prognosis of Elderly Patients with Multiple Myeloma
- Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Randomized Clinical Trials
- Exploring natural killer cell-related biomarkers in multiple myeloma: a novel nature killer cell-related model predicting prognosis and immunotherapy response using single-cell study
- Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives
- EZH2 Promotes Multiple Myeloma Progression via STAT3 Pathway Activation
- Genetic risk factors for bortezomib-induced neuropathic pain in an Asian population: A genome-wide association study in South Korea
- Genomic Frequencies of Dynamic DNA Sequences and Mammalian Lifespan
- Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma
- How to manage poor mobilisers
- Immune escape of multiple myeloma cells results from low miR29b and the ensuing epigenetic silencing of proteasome genes
- Immune Therapies in AL Amyloidosis-A Glimpse to the Future
- Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study
- Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial
- Implementing multi-level network meta-regression for time-to-event outcomes: A case study in relapsed refractory multiple myeloma
- Implications and hidden toxicity of cardiometabolic syndrome and early-stage heart failure in carfilzomib-induced cardiotoxicity
- Investigation of polypharmacy, antimicrobial-related potential drug-drug interactions in patients with hematological malignancies
- Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial
- Langerhans Cell Histiocytosis Mimicking a Meningeal Lesion with Temporal Bone and Muscle Compromise in an Adult Patient: A Case Report
- Lenalidomide-induced psoriasis in a refractory multiple myeloma patient successfully treated with narrowband ultraviolet B
- Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial
- Metabolic signature and response to glutamine deprivation are independent of p53 status in B cell malignancies
- MicroRNAs predict early complications of autologous hematopoietic stem cell transplantation
- Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions
- Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light-Chain Amyloidosis: Real-World Experience in Clinical Characteristics and Treatment-67 Patients Multicenter Analysis
- Outcomes of percutaneous vertebroplasty in multiple myeloma: a tertiary neurosciences experience with long-term follow-up
- Overtreatment of multiple myeloma and its precursor states: de-escalation is an urgent need in clinical practice and trials
- Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
- Plasmablastic myeloma transformation of light-chain multiple myeloma
- PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of elranatamab for multiple myeloma, CPX-351 for myeloid leukemia, inotuzumab ozogamicin for lymphoblastic leukemia, capivasertib for breast cancer, a
- Preoperative diagnosis and safe surgical approach in gallbladder amyloidosis: a case report
- Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
- Proteasome inhibitor bortezomib prevents proliferation and migration of pulmonary arterial smooth muscle cells
- Real-World Registry on the Pharmacotherapy of Multiple Myeloma and Associated Renal and Pulmonary Impairments in the Greater Gulf Region: Protocol for a Retrospective Real-World Data Study
- Recent advances in the treatment and prevention of peripheral neuropathy after multiple myeloma treatment
- Research Progress on the Role of Berberine in Hematologic Malignancies and Its Related Mechanisms --Review
- Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance
- Results of Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma(MM) and Renal Impairment: A Retrospective Single-Center Study
- Role of Immune Cells and Immunotherapy in Multiple Myeloma
- Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review
- Selenoprotein W engages in overactive osteoclast differentiation in multiple myeloma
- Self-sufficient primary natural killer cells engineered to express T cell receptors and interleukin-15 exhibit improved effector function and persistence
- Serum Levels of miR-122-5p and miR-125a-5p Predict Hepatotoxicity Occurrence in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation
- Seven-year Follow-up of India's First Sequential Hematopoietic Stem Cell and Kidney Transplant for Multiple Myeloma
- Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients
- Small intestinal angiodysplasia and hemorrhage associated with acquired von Willebrand syndrome type 2A secondary to multiple myeloma: Reversal after treatment with IRD regimen (a case report and a brief review of the literature)
- Solitary Bone Plasmacytoma of the Skull Base With an Unusual Presentation
- Supportive care measures for bispecific T-cell engager therapies in haematological malignancies
- T cell characteristics impact response and resistance to T cell-redirecting bispecific antibodies in multiple myeloma
- T-Cell Engagers-The Structure and Functional Principle and Application in Hematological Malignancies
- Tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma: a systematic review and meta-analysis
- Targeted therapy for multiple myeloma: an overview on CD138-based strategies
- The eEF1A Protein in Cancer: Clinical Significance, Oncogenic Mechanisms, and Targeted Therapeutic Strategies
- The Efficacy of Carfilzomib Treatment in Bortezomib-Refractory Patients-Real Life Experience in a Tertiary Romanian Hospital
- The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression
- The relationship between patient-reported and objective measures of physical function among cancer survivors receiving rehabilitation care: A correlation analysis
- The role of proliferating stem-like plasma cells in relapsed or refractory multiple myeloma: Insights from single-cell RNA sequencing and proteomic analysis
- Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma
- Tixagevimab/cilgavimab (AZD7442/Evusheld) prevent from COVID19 in patients with hematologic malignancies under active chemotherapy
- Ubiquitin-specific protease 7 inhibitors reveal a differentiated mechanism of p53-driven anti-cancer activity
- Unique cutaneous metastasis of multiple myeloma
- Unveiling the Uncommon: A Unique Case of ALPS-Like Syndrome Complicated by Plasma Cell Disorder
- XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways